Statin Therapy Guidelines for Optimal LDL-C Reduction

Introduction to Statin Therapy

The American College of Cardiology recommends starting with high-intensity statin therapy (atorvastatin 40-80mg or rosuvastatin 20-40mg) as the foundation for patients requiring combination lipid-lowering therapy 5
The American Heart Association suggests that simvastatin 40mg is classified as only moderate-intensity statin therapy, providing 30-49% LDL-C reduction, whereas current guidelines prioritize high-intensity statins (≥50% LDL-C reduction) for most patients with established cardiovascular disease 4

Atorvastatin 80mg or rosuvastatin 20-40mg provide approximately 50% or greater LDL-C reduction as monotherapy, making them more potent baseline options before adding ezetimibe 5
The combination of rosuvastatin with ezetimibe has demonstrated excellent efficacy and tolerability, with fixed-dose combinations achieving >50% LDL-C reduction from baseline 5

Current guidelines recommend adding ezetimibe 10mg if LDL-C remains above goal after 4-6 weeks of high-intensity statin therapy 5, 6
If LDL-C goals are still not achieved, consider adding a PCSK9 inhibitor (evolocumab or alirocumab) to the high-intensity statin plus ezetimibe regimen 5

For patients requiring combination lipid-lowering therapy, start with high-intensity statin monotherapy (atorvastatin 40-80mg or rosuvastatin 20-40mg) as the foundation 5
Add ezetimibe 10mg if LDL-C remains above goal after 4-6 weeks of high-intensity statin therapy 5, 6

The IMPROVE-IT trial demonstrated cardiovascular benefit with simvastatin 40mg/ezetimibe 10mg, but this was a 6-year trial that began enrollment before modern high-intensity statin guidelines were established 1, 2, 3
The absolute risk reduction was only 2.0 percentage points (32.7% vs 34.7%), requiring treatment of 56 patients to prevent one event 2